Leadership

Kim serves as CENTOGENE’s Chief Executive Officer.

Kim has more than 25 years’ global commercial expertise in the biopharmaceutical space, with significant experience across multiple geographies, including the U.K., U.S., Europe, and emerging markets. Most recently, Kim was CEO of Orphazyme, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases. Prior to this role, she worked at Shire Pharmaceuticals, where she served as Head International Commercial for Shire’s Specialty and Rare Diseases portfolio. Before Shire, Kim spent nearly 15 years at Novartis in a number of senior management roles, including global product development, commercial, marketing, general manager, and various global corporate functions, including government and external affairs. Kim is on the Board of Recordati S.p.A, Novozymes A/S and Vifor Pharma AG.

Prof. Peter Bauer, M.D., serves as CENTOGENE's Chief Genomic Officer, where he combines an extensive clinical and medical understanding of genetic testing with an excellent knowledge of the latest scientific developments.

Peter is passionate about turning medical questions into complete and fast analytical processes – ensuring that medically-driven results are brought to clinicians and patients immediately.

He received his board certification in Human Genetics in 2006 and previously headed the Molecular Diagnostic Laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Additionally, he is Vice President of the German Society of Neurogenetics (DGNG). Peter has authored more than 140 publications in Neurogenetics, Oncogenetics, Cardiogenetics, and Sequencing Technology.

Patrice P. Denèfle serves as CENTOGENE’s Chief Scientific Officer. Within this role, he is responsible for overseeing the company’s scientific activities to deliver on its vision and strategy, while driving value creation.

Patrice is a seasoned executive and scientific pioneer with over 35 years of experience at pharmaceutical and biotechnology companies in Europe and the U.S. – spearheading translational R&D to deliver breakthrough treatments to patients.  

Prior to joining CENTOGENE, Patrice served as Chief Scientific Officer at 4P-Pharma, where he led the R&D drug repositioning strategy and operations towards potential full clinical demonstration and asset-value transfer to large pharma companies. Over the past three decades, he has held several leadership positions, including as the General Manager of the Roche Institute for Research and Translational Medicine, as well as other senior roles at Sanofi Aventis and Ipsen. Patrice also served as CSO at Genethon, a biotech company dedicated to the development of gene therapy treatments for rare diseases.  

Patrice received his Ph.D. in Molecular Biology and Biotechnology from the Pasteur Institute, Paris, completed his HDR (Habilitation) in Molecular Pharmacology at the University of Lille, graduated as Adjunct University Professor, and taught Biotechnology for 10 years at the University Paris-Descartes. He was also trained as a CEDEP fellow at INSEAD and has co-authored more than 150 scientific papers and patents.